Compare Stocks: CUE, SLN, FDMT, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$27.88 -1.0%	$29.30	$4.97 ▼ $45.50	$202.53M	2.47	197,614 shs	102,248 shs
FDMT 4D Molecular Therapeutics	$14.67 -1.6%	$12.21	$5.97 ▼ $16.93	$810.43M	2.73	1.04 million shs	1.10 million shs
NVCT Nuvectis Pharma	$23.73 -5.8%	$20.74	$5.55 ▼ $29.27	$774.64M	-0.26	223,538 shs	137,203 shs
SLN Silence Therapeutics	$13.42 -0.2%	$11.49	$4.19 ▼ $17.58	$808.01M	1.39	1.90 million shs	539,702 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	0.00%	+16.26%	-8.29%	+27.31%	-96.27%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+45.68%	+48.03%	+127.09%
NVCT Nuvectis Pharma	0.00%	+0.72%	+4.26%	+143.38%	+256.84%
SLN Silence Therapeutics	0.00%	+1.13%	+15.49%	+94.49%	+158.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$27.88 -1.0%	$29.30	$4.97 ▼ $45.50	$202.53M	2.47	197,614 shs	102,248 shs
FDMT 4D Molecular Therapeutics	$14.67 -1.6%	$12.21	$5.97 ▼ $16.93	$810.43M	2.73	1.04 million shs	1.10 million shs
NVCT Nuvectis Pharma	$23.73 -5.8%	$20.74	$5.55 ▼ $29.27	$774.64M	-0.26	223,538 shs	137,203 shs
SLN Silence Therapeutics	$13.42 -0.2%	$11.49	$4.19 ▼ $17.58	$808.01M	1.39	1.90 million shs	539,702 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	0.00%	+16.26%	-8.29%	+27.31%	-96.27%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+45.68%	+48.03%	+127.09%
NVCT Nuvectis Pharma	0.00%	+0.72%	+4.26%	+143.38%	+256.84%
SLN Silence Therapeutics	0.00%	+1.13%	+15.49%	+94.49%	+158.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	1.00	Sell	N/A	N/A
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	101.94% Upside
NVCT Nuvectis Pharma	2.50	Moderate Buy	$35.00	47.49% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	298.66% Upside

Current Analyst Ratings Breakdown

Latest CUE, SLN, FDMT, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$27.47M	7.37	N/A	N/A	$10.08 per share	2.77
FDMT 4D Molecular Therapeutics	$85.21M	9.51	N/A	N/A	$8.85 per share	1.66
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
SLN Silence Therapeutics	$560K	1,442.89	N/A	N/A	$1.32 per share	10.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/12/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest CUE, SLN, FDMT, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.25	1.25
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
NVCT Nuvectis Pharma	N/A	1.68	1.68
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
FDMT 4D Molecular Therapeutics	99.27%
NVCT Nuvectis Pharma	96.77%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	14.56%
FDMT 4D Molecular Therapeutics	7.90%
NVCT Nuvectis Pharma	28.55%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	7.26 million	6.21 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
NVCT Nuvectis Pharma	8	32.64 million	23.32 million	Not Optionable
SLN Silence Therapeutics	100	60.21 million	58.40 million	Not Optionable

CUE, SLN, FDMT, and NVCT Headlines

Recent News About These Companies

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Research Analysts Issue Forecasts for SLN Q3 Earnings

August 20, 2026 | americanbankingnews.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18, 2026 | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17, 2026 | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

Silence Therapeutics stock surges as divesiran trial results fuel optimism

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, SLN, FDMT, and NVCT Company Descriptions

Cue Biopharma NASDAQ:CUE

$27.88 -0.28 (-0.99%)

As of 08/28/2026 04:00 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$14.67 -0.24 (-1.61%)

As of 08/28/2026 04:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Nuvectis Pharma NASDAQ:NVCT

$23.73 -1.46 (-5.80%)

As of 08/28/2026 04:00 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Silence Therapeutics NASDAQ:SLN

$13.42 -0.03 (-0.22%)

As of 08/28/2026 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, SLN, FDMT, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, SLN, FDMT, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, SLN, FDMT, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, SLN, FDMT, and NVCT Company Descriptions

Cue Biopharma NASDAQ:CUE

4D Molecular Therapeutics NASDAQ:FDMT

Nuvectis Pharma NASDAQ:NVCT

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, SLN, FDMT, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, SLN, FDMT, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, SLN, FDMT, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, SLN, FDMT, and NVCT Company Descriptions

Cue Biopharma NASDAQ:CUE

4D Molecular Therapeutics NASDAQ:FDMT

Nuvectis Pharma NASDAQ:NVCT

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools